Current Good Manufacturing Practice for Finished Pharmaceuticals
The foundational cGMP regulation governing finished pharmaceutical manufacturing in the US market. Establishes minimum quality standards for organization, buildings, equipment, production, packaging, and records.
Applies to all manufacturers, processors, packagers, and holders of finished pharmaceuticals intended for human use and distributed in the United States.
- 01Written procedures required for all GMP operations with second-person verification
- 02Equipment qualification and calibration records maintained and current
- 03Production and process controls validated with documented protocols and reports
- 04Out-of-specification (OOS) investigations must be thorough with root cause identified
- 05Batch records reviewed and approved before product release
- 06Laboratory controls including method validation and instrument qualification
- 07Complaint handling and annual product review programmes
April 2023 update clarified electronic data integrity expectations in line with FDA data integrity guidance. No structural changes to core GMP requirements.
21 CFR Part 211: frequently asked questions
Quick answers to common questions about 21 CFR Part 211.
What is 21 CFR Part 211?
21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals — is a regulation issued by the Food and Drug Administration (United States). The foundational cGMP regulation governing finished pharmaceutical manufacturing in the US market. Establishes minimum quality standards for organization, buildings, equipment, production, packaging, and records.
Who does 21 CFR Part 211 apply to?
Applies to all manufacturers, processors, packagers, and holders of finished pharmaceuticals intended for human use and distributed in the United States.
What are the key requirements of 21 CFR Part 211?
FDA 21 CFR Part 211 requires, among other things: Written procedures required for all GMP operations with second-person verification; Equipment qualification and calibration records maintained and current; Production and process controls validated with documented protocols and reports; Out-of-specification (OOS) investigations must be thorough with root cause identified.
When was 21 CFR Part 211 last updated?
The current version of 21 CFR Part 211 dates from April 2023. April 2023 update clarified electronic data integrity expectations in line with FDA data integrity guidance. No structural changes to core GMP requirements.
Ready-to-use templates designed to help you comply with 21 CFR Part 211.
Browse 1 related template →Live openFDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.
Track the standards that move
When 21 CFR Part 211 — or any GxP requirement — is revised, recalled against, or clarified by new guidance, the Weekly GxP Briefing surfaces it. Free, one email a week.